


Osilodrostat phosphate

Chemical Properties

CAS No. :	1315449-72-9
Formula:	C ₁₃ H ₁₃ FN ₃ O ₄ P
Molecular Weight:	325.23
Storage:	Powder: -20°C for 3 years In solvent: -80°C for 1 year Actual storage temperature shall be subject to the COA.



Biological Description

Description	Osilodrostat phosphate is a potent oral 11 β -hydroxylase inhibitor.
Targets(IC50)	Glucocorticoid Receptor,Others

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	3.0747 mL	15.3737 mL	30.7475 mL
5 mM	0.6149 mL	3.0747 mL	6.1495 mL
10 mM	0.3075 mL	1.5374 mL	3.0747 mL
50 mM	0.0615 mL	0.3075 mL	0.6149 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Cuevas-Ramos D, Lim DST, Fleseriu M. Update on medical treatment for Cushing's disease. Clin Diabetes Endocrinol. 2016 Sep 13;2:16. doi: 10.1186/s40842-016-0033-9. eCollection 2016. Review. PubMed PMID: 28702250; PubMed Central PMCID: PMC5471955.

Armani S, Ting L, Sauter N, Darstein C, Tripathi AP, Wang L, Zhu B, Gu H, Chun DY, Einolf HJ, Kulkarni S. Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults. Clin Drug Investig. 2017 May;37(5):465-472. doi: 10.1007/s40261-017-0497-0. PubMed PMID: 28155129; PubMed Central PMCID: PMC5394143.

Fleseriu M, Castinetti F. Updates on the role of adrenal steroidogenesis inhibitors in Cushing's syndrome: a focus on novel therapies. Pituitary. 2016 Dec;19(6):643-653. Review. PubMed PMID: 27600150; PubMed Central PMCID: PMC5080363.

Fleseriu M, Pivonello R, Young J, Hamrahian AH, Molitch ME, Shimizu C, Tanaka T, Shimatsu A, White T, Hilliard A, Tian C, Sauter N, Biller BM, Bertagna X. Osilodrostat, a potent oral 11 β -hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease. Pituitary. 2016 Apr;19(2):138-48. doi: 10.1007/s11102-015-0692-z. PubMed PMID: 26542280; PubMed Central PMCID: PMC4799251.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481